Ab­b­Vie scores a key win in Alzheimer's drug patent suit

A Cal­i­for­nia fed­er­al ap­peals court on Thurs­day let Ab­b­Vie off the hook from a whistle­blow­er law­suit al­leg­ing the com­pa­ny held fraud­u­lent patents on two Alzheimer’s drugs, there­fore over­charg­ing Medicare.

The case traces back to a com­plaint filed by patent lawyer Zachary Sil­ber­sh­er back in 2018, ac­cus­ing Al­ler­gan of with­hold­ing in­for­ma­tion from the Patent Trade­mark Of­fice that may have led the agency to re­ject patents for Na­men­da XR and Namzaric, ex­tend­ed re­lease drugs to treat Alzheimer’s-as­so­ci­at­ed de­men­tia. Ab­b­Vie swal­lowed Al­ler­gan for $63 bil­lion in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER